RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42660113.
- Also identified by DOI 10.1016/j.xcrm.2026.103010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Development of bone metastases increases mortality in patients with medullary thyroid cancer (MTC), with ∼50% survival at 5 years after diagnosis, but the underlying mechanisms of action are unknown. We show that patient-derived MTC cells (RET<sup>C634W</sup> mutant TT and RET<sup>M918T</sup> mutant MZCRC1 cells) promote osteoblastic phenotypes due to reduced osteoclastic bone resorption. Mechanistically, activated RET increases osteoprotegerin (OPG) expression, an inhibitor of bone resorption, leading to decreased osteoclast differentiation. Furthermore, RET knockdown or pharmacological RET inhibition attenuates tumor burden and osteoblastic lesions in MTC-bearing mouse femurs. Circulating levels of OPG in humans increase in the plasma of patients with MTC and MTC bone metastases, and these levels are associated with poor overall survival. Patients who receive multi-kinase inhibitors have lower circulating OPG levels. These findings reveal a potential link between RET signaling and aberrant osteoblastic bone formation during tumor metastasis and suggest OPG as a potential biomarker for MTC bone metastases.